Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Latest News about Hemophilia A

Recent news which mentions Hemophilia A

Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients
Tickers BIOVF SNY
Tags Briefs Phase 3 Results BIOVF
From Benzinga
BioMarin's Hemophilia Gene Therapy Meets Efficacy Endpoints At Two Year Analysis
Tickers BMRN
Tags General Hemophilia A News
From Benzinga
Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients
Tickers SNY
Tags hemophilia B Market News SNY
From Benzinga
Generation Bio Hits 52-Week Low After Preclinical Data From Hemophilia A Program
Tickers GBIO
Tags Market News Movers Preclinical Phase
From Benzinga
Sigilon Therapeutics Issues An Update On Its Early-Stage Hemophilia Study
Tickers SGTX
Tags Market News Health Care Penny Stocks
From Benzinga
Centessa Stock Surges On Positive Data From Hemophilia Candidate
Tickers CNTA
Tags Health Care Phase 2 Trial Hemophilia
From Benzinga
BioMarin Shares 5-Year Data From Open-Label Trial Of Hemophilia Gene Therapy
Tickers BMRN
Tags Phase 2 Trial gene therapy Health Care
From Benzinga
Spark Therapeutics' Hemophilia Gene Therapy Achieve Stable, Durable FVIII Expression
Tickers RHHBF RHHBY RHHVF
Tags RHHBY gene therapy RHHBF
From Benzinga
Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A
Tickers RHHBF RHHBY RHHVF
Tags Briefs Benzinga Hemophilia A
From Benzinga
BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22
Tickers BMRN
Tags Briefs Health Care General
From Benzinga
Serious Adverse Event Triggers FDA Clinical Hold On Sigilon Therapeutics' Hemophilia A Trial, Shares Drop
Tickers SGTX
Tags General Hemophilia A Biotech
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.